Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,042 total articles
Chewy trades like a recovering growth retailer with defensive demand traits: a $10.8B market cap, a high recurring revenue mix from Autoship, and improving cash flow. At $26.14 the risk/reward favors a long trade targeting $35 over the next 180 trading days, while protecting capital with a $23 stop.
Aurora Cannabis (ACB) trades at a sub-$200M market cap with a P/B near 0.54 and meaningful short interest. Regulatory moves in the U.S., ongoing industry premiumization, and the company’s downsized cost base create an asymmetric risk/reward for a mid-term trade. I outline an entry at $3.385, a stop at $2.90 and a $5.50 target tied to a ~60-65% upsi…
XOP offers a way to buy a diversified, equal-weighted basket of U.S. exploration & production names that have already recovered from 52-week lows but remain below recent highs. With a $3.23B market cap, a 2.07% yield and technicals near neutral, this ETF is a pragmatic swing trade: entry $168.00, stop $160.00, target $190.00 over a mid-term horizon…
Eli Lilly (LLY) has the balance sheet, cash flow, and a leading GLP-1 franchise to recover from recent volatility. The stock is trading off materially from its highs and the technicals are soft, so the trade is a tactical mid-term long: enter at $880.00, stop at $820.00, target $980.00 over ~45 trading days. Keep position size disciplined — this is…
Freeport-McMoRan (FCX) dipped after a Grasberg delay and guidance cut, creating a tactical long opportunity. With market cap around $87.7B, EV/EBITDA near 10.7 and free cash flow of ~$1.12B, the company can ride a copper rebound if supply tightness persists. Trade plan: enter $61.05, target $70.00, stop $57.00 - mid-term (45 trading days) swing.
UnitedHealth (UNH) delivered a convincing Q1, raised full-year guidance and reinstated buybacks, signaling a recovery. Fundamentals have improved - medical cost trends, Optum momentum and $2B in buybacks matter - but technicals are stretched (RSI ~82) and valuation is full. This trade proposes a measured long on a pullback with clear stop and targe…
Medpace remains a high-quality contract research organization with durable free cash flow and elevated margins. Recent weakness has brought the stock down toward technical support and improved entry economics, but multiple securities class actions and book-to-bill questions introduce headline risk. I downgrade my conviction but maintain a Buy trade…
Adobe's shares have been punished on AI worries and technical weakness, but the underlying business still generates healthy margins and free cash flow. With a $25 billion buyback, strong FCF ($10.317B), and valuation metrics that look reasonable (PE ~14.5, EV/EBITDA ~10.1), the stock offers a compelling risk-reward for a long-term trade. This idea …
Information Services Group (III) is trading cheaply relative to its cash generation. A cyclical slowdown has pressured margins and near-term earnings, but ISG's $25m annual free cash flow, modest leverage and a ~4% dividend create a low-risk entry for a long-term trade. Entry $4.05, stop $3.50, target $5.50 over 120 trading days.
Planet Labs is riding favorable sector momentum and meaningful defense wins, but the stock already prices aggressive future growth. We upgrade to a tactical long with a clearly defined entry, stop and target for a long-term (180 trading days) hold — this is a high-risk, high-reward trade that depends on contract execution and sustained margin impro…
Toast just crossed the profitability Rubicon. With $608M in free cash flow, $342M in net income on $6.2B revenue, and an institutional buyer stepping in, the stock offers a favorable asymmetric swing opportunity around $28.35. This trade pairs a clear entry and stop with a realistic upside target backed by improving fundamentals, resilient unit eco…
Alpha Metallurgical (AMR) offers a mid-term buying opportunity. The stock has corrected from its January highs, valuation multiples are reasonable on a P/B basis, and AMR's met coal focus positions it to benefit if import demand from India firm up. The trade is a guarded long with clearly defined entries, stop and target while acknowledging executi…
Wesdome offers exposure to high-grade underground gold production with a compact asset base and clear near-term catalysts (Kiena ramp, drilling results, potential M&A optionality). We set a tactical long trade with a defined entry, stop and target and a long-term horizon to capture operational derisking and re-rating.
Charter (CHTR) plunged into oversold territory after a sharp intra-day move, but the company's cash generation, low earnings multiple and clear operational catalysts make a controlled long the highest-probability trade. Entry at $184.94, stop at $174.00, target $258.11 — mid-term setup with room to extend on confirming data.
CAE is trading like it will re-accelerate into 2027, but legacy Defense contract issues, a lowered EPS growth target and stretched valuation argue otherwise. This note lays out a short trade: entry $25.25, stop $28.50, target $20.00, horizon 180 trading days. Catalyst calendar and risk checklist included.
TransDigm (TDG) has been punished on concerns around commercial exposure. The pullback creates an actionable long setup: the business prints industry-leading operating margins, generates roughly $1.88B in free cash flow and has an enterprise value of ~$93.4B - metrics that argue the current price understates resilience. We lay out an entry at $1,15…
Tesla's $25B-plus capex plan for 2026 spooked the market, but the company is investing in AI, robotics, chips and robotaxi hardware that can expand margins and create new high-margin services. Fundamentals show growth (16% sales growth in the quarter) and steady free cash flow ($6.22B reported) even with heavy investment plans. Technicals and senti…
Anterix owns one of the most strategically valuable spectrum positions for utilities and critical infrastructure. With a market cap near $840M, strong ROE, no debt and improving commercial traction, the stock looks mispriced versus the optional value embedded in 900 MHz. This trade idea lays out a concrete entry, stop and $75 target on a long-term …
Quest Diagnostics (DGX) looks like a reliable, cash-generative diagnostics platform with a modest valuation and technical momentum. A clear entry, stop and target give a sensible risk/reward for a position lasting up to 180 trading days while catalysts like dividend growth, increased buybacks and secular demand in esoteric testing support upside.
Intel's Q1 2026 results and updated guidance reframed the company as a core AI infrastructure play. Revenue of $13.58B and adjusted EPS of $0.29 surprised the market, data center sales grew 22%, and management says AI-related businesses now represent roughly 60% of revenue. The stock has ripped higher, so this is a structured long: enter at $82.75,…
RELX is a defensive business-information franchise that has seen its multiple reprice amid sector-wide AI fears. Recent customer wins, proof points of pricing power in legal services, and bullish technicals offer an actionable long setup. Entry $36.33, stop $33.00, target $44.00 for a mid-term (45 trading days) recovery trade.
Total Energy Services has run hard, but the operational cadence of well servicing, improving utilization and a conservative balance sheet still support a mid-term long. This trade idea gives a precise entry, stop and target with clear time horizons and risk framing for disciplined execution.
Legend Biotech (LEGN) is a commercially active CAR-T company whose CARVYKTI franchise is already generating meaningful revenue. At a $4.54B market cap the stock discounts a lot of upside from earlier-line indications, manufacturing expansion and healthy commercial metrics. Technicals show bullish momentum and short interest remains elevated, creati…
First American Financial offers a blend of defensive earnings from title and specialty insurance plus upside from a cyclical housing rebound. At roughly $70.53 with a P/E in the low-teens and $763M in free cash flow, the stock is set up for a tactical long into a recovering mortgage market. This trade outlines entry, stop and target with risk frami…
Credo (CRDO) just bought a silicon photonics specialist and management is forecasting more than $500M in optical revenue by fiscal 2027. With no debt, solid free cash flow and accelerating product cycles for AI data centers, the risk/reward for a mid-term long trade looks favorable despite lofty multiples. This trade idea lays out entry, stop, targ…
